ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Indian generic drugs company Cipla will spend about $20 million to build a biosimilars plant in Durban, South Africa. Scheduled to come on-line in 2018, the plant, which will mostly produce cancer drugs, will employ about 300 people. Cipla says it hopes that its investment will help make biologic drugs affordable for 20% of the country’s patients, up from just 2% currently.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter